What is the recommended approach to diagnose and treat hepatitis C in an adult patient, including necessary baseline testing (quantitative HCV RNA, genotype, liver fibrosis assessment) and first‑line antiviral regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Hepatitis C: Diagnosis and Treatment Approach

For adult patients with hepatitis C, screen with HCV antibody testing with reflex to quantitative HCV RNA (≤25 IU/mL detection), assess liver fibrosis using non-invasive markers (FIB-4 or APRI), and treat treatment-naïve patients without cirrhosis or with compensated cirrhosis using pangenotypic regimens: glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks—genotyping is no longer required for these patients. 1, 2

Diagnostic Approach

Initial Screening and Confirmation

  • Screen with HCV antibody testing in all adults ≥18 years at least once, during each pregnancy, and periodically in those with ongoing risk factors 1, 3
  • Reflex to quantitative HCV RNA testing automatically when antibody is positive—this single blood draw approach prevents loss to follow-up 1
  • Use FDA-approved HCV RNA assay with detection level ≤25 IU/mL 1
  • Positive HCV RNA confirms active infection requiring treatment 1, 3

Baseline Assessment Before Treatment

Essential testing:

  • Quantitative HCV RNA (viral load) 1
  • Liver fibrosis assessment using non-invasive markers 1, 2:
    • FIB-4 or APRI scores are sufficient for initial stratification
    • Determines treatment duration and need for post-treatment surveillance
    • If unavailable, use universal 12-week treatment duration 2

Genotyping is NOT required for treatment-naïve patients without cirrhosis using pangenotypic regimens 1, 2. Only obtain genotype if patient has prior treatment failure, as this affects retreatment selection 1.

Additional baseline evaluation:

  • Screen for hepatitis B and HIV coinfection 1
  • Check for drug-drug interactions with planned DAA regimen 2
  • Vaccinate against hepatitis A and B if susceptible 1

Treatment Recommendations

First-Line Regimens for Treatment-Naïve Adults

Without cirrhosis:

  • Glecaprevir/pibrentasvir: 8 weeks (all genotypes) 2, 3
  • Sofosbuvir/velpatasvir: 12 weeks (all genotypes) 2, 3

With compensated (Child-Pugh A) cirrhosis:

  • Glecaprevir/pibrentasvir: 12 weeks 2
  • Sofosbuvir/velpatasvir: 12 weeks 2

These pangenotypic regimens achieve >95% cure rates across all genotypes 3, 4. The choice between them depends primarily on drug-drug interactions and local availability 2.

Genotype-Specific Alternatives (When Genotyping Available)

If pangenotypic regimens are unavailable, older genotype-specific options from 2015-2017 guidelines include 5, 6:

Genotype 1a (treatment-naïve):

  • Ledipasvir/sofosbuvir 12 weeks (no cirrhosis) or 24 weeks (cirrhosis)
  • Avoid simeprevir/sofosbuvir in cirrhotic patients with Q80K polymorphism 5

Genotype 1b (treatment-naïve):

  • Ledipasvir/sofosbuvir 12 weeks
  • Paritaprevir/ritonavir/ombitasvir plus dasabuvir 12 weeks 5

Genotype 2:

  • Sofosbuvir plus weight-based ribavirin 12 weeks (extend to 16 weeks with cirrhosis) 5

Genotype 3:

  • Most difficult to treat; sofosbuvir plus ribavirin 24 weeks 5

Genotypes 4,5,6:

  • Ledipasvir/sofosbuvir 12 weeks 5

Treatment Monitoring and Follow-Up

During Treatment

  • On-treatment monitoring is optional unless clinically indicated 4
  • This simplified approach reduces barriers to treatment completion

Post-Treatment

  • Confirm cure with HCV RNA at 12 weeks post-treatment (sustained virologic response, SVR12) 3, 4
  • SVR12 is associated with lower all-cause mortality and improved quality of life 3, 7

Long-Term Surveillance (If Advanced Fibrosis/Cirrhosis Present)

  • Hepatocellular carcinoma screening: Abdominal ultrasound ± alpha-fetoprotein every 6 months 3
  • Esophageal varices screening: Upper endoscopy every 2-3 years 3
  • If no cirrhosis: No liver-related follow-up needed after SVR 3

Key Clinical Pitfalls

Drug interactions: Carefully check interactions, particularly:

  • Ledipasvir/sofosbuvir with proton pump inhibitors 5
  • Paritaprevir/ritonavir/ombitasvir with CYP3A4 substrates (e.g., salmeterol) 5

Cirrhosis assessment matters: Treatment duration differs between non-cirrhotic and cirrhotic patients with certain regimens 5, 2. Use FIB-4 or APRI if formal assessment unavailable—when in doubt, treat for 12 weeks 2.

Reinfection risk: Patients with ongoing risk behaviors need annual HCV RNA testing after SVR 2. Counsel on harm reduction 1.

Treatment-experienced patients: Those who failed prior DAA therapy require genotyping and specialist referral, as resistance-associated substitutions affect retreatment selection 5.

Younger patients benefit most: Achieving SVR before age 50 in patients with mild fibrosis results in mortality rates similar to the general population 7. This emphasizes treating early rather than waiting.

References

3
Research

Hepatitis C: Diagnosis and Management.

American family physician, 2021

Related Questions

What is the appropriate approach to evaluate and manage a 45-year-old male with incidentally detected reactive hepatitis C virus (HCV) RNA?
In a 46-year-old male with a positive anti‑HCV antibody, HCV RNA of 2,283,553 IU/mL, normal liver function tests, normal abdominal ultrasound, and normal FibroScan, what is the appropriate management?
What is the recommended treatment for hepatitis C virus infection in adults?
In a 32-year-old patient with a history of intravenous drug use and hepatitis C who presents with new-onset edema and a low‑normal ejection fraction (50‑55%) on an otherwise normal echocardiogram, what laboratory tests should be ordered?
When should chronic hepatitis C infection be treated?
What baseline anticoagulation panel should be obtained for a patient who is starting or currently receiving anticoagulant therapy?
In a 40-year-old patient with cerebrospinal fluid showing 218 erythrocytes and 8 polymorphonuclear cells, what are the possible causes?
An elderly patient who completed oral cephalexin for lower extremity cellulitis now has a swollen, markedly erythematous limb. What is the appropriate intravenous antibiotic regimen, including dose and duration?
I have worsening back pain, generalized weakness, muscle wasting in the thighs and hips, a metallic taste, rapid weight loss of about 3–4 lb overnight, normal CBC and CMP, and a brain MRI performed Tuesday with results pending—could this indicate an emergent condition and what steps should I take?
What is the appropriate dosing, titration, and safety monitoring when starting empagliflozin (Jardiance) together with glimepiride?
For a 39‑year‑old woman who experienced a mild reaction within two minutes of a ferric carboxymaltose (Ferrinject) infusion, what alternative intravenous iron preparations can be considered?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.